Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.
The company's shares are trading at their lowest since August 2023. Source: xStation
ASML āļĢāđāļ§āļāđāļĢāļ: āļāļ§āļēāļĄāļāļąāļāđāļĨāļ°āļāđāļēāļ§āļĨāļ·āļāļĒāļąāļāđāļĄāđāļŠāļēāļĄāļēāļĢāļāļāļģāļĨāļēāļĒāļāļēāļĢāļāļđāļāļāļēāļāđāļāđ
āļāļĨāļāļĢāļ°āļāļāļāļāļēāļĢ Mercedes: āļāļ§āļēāļĄāđāļāļ·āđāļāļĄāļąāđāļāļāļĩāđāļĄāļĩāđāļŦāļāļļāļāļĨāļĢāļāļāļĢāļąāļāļŦāļĢāļ·āļāđāļĄāđ?
āļāļĢāļąāđāļāđāļĻāļŠāļāđāļēāļāļ Palantir āļāļĨāļēāļāļāļāļāļŠāļāļāļāļāļąāļāļāļĩ
āļāđāļēāļ§āđāļāđāļāļ§āļąāļāļāļĩāđ 29 āļ.āļ.
